Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wei-Yang Chang

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
BMC Sports Science, Medicine & Rehabilitation|April 30, 2025
Physical fitness predicts post-esophagectomy complications after chemoradiotherapy: a pilot studyChien-Hung Chiu, Wei-Yang Chang, Lan-Yan Yang, et al.
Current Oncology (Toronto, Ont.)|October 27, 2022
Management and Prognosis of Patients with Recurrent or Persistent/Progressive Uterine CarcinosarcomaHsiu-Jung Tung, Chi-Yuan Chiang, Wei-Yang Chang, et al.
Journal of the Chinese Medical Association : JCMA|November 8, 2021
Serum levels of alpha1-antitrypsin isoforms in patients with ovarian clear cell carcinoma: An exploratory studySung-Yao Chen, Ting-Chang Chang, Chiao-Yun Lin, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|April 9, 2017
Clear cell carcinomas of the ovary have poorer outcomes compared with serous carcinomas: Results from a single-center Taiwanese studyFei-Chun Ku, Ren-Chin Wu, Lan-Yan Yang, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|May 13, 2021
Postoperative adjuvant dose-dense chemotherapy with bevacizumab and maintenance bevacizumab after neoadjuvant chemotherapy for advanced ovarian cancer: A phase II AGOG/TGOG trialHung-Hsueh Chou, Wei-Chun Chen, Lan-Yan Yang, et al.
Journal of Molecular Medicine (Berlin, Germany)|May 5, 2018
Genomic scar signatures associated with homologous recombination deficiency predict adverse clinical outcomes in patients with ovarian clear cell carcinomaAngel Chao, Chyong-Huey Lai, Tzu-Hao Wang, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 11, 2016
Utility of (18)F-FDG PET/CT in patients with advanced squamous cell carcinoma of the uterine cervix receiving concurrent chemoradiotherapy: a parallel study of a prospective randomized trialFeng-Yuan Liu, Chyong-Huey Lai, Lan-Yan Yang, et al.
Journal of Gynecologic Oncology|January 9, 2020
<i>BRCA1/2</i> mutation status in patients with metachronous breast and ovarian malignancies: clues towards the implementation of genetic counselingAngel Chao, Yi Hao Lin, Lan Yan Yang, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|December 11, 2019
Management and clinical outcomes of patients with recurrent/progressive ovarian clear cell carcinomaHuei-Jean Huang, Lan-Yan Yang, Hsiu-Jung Tung, et al.
Taiwanese Journal of Obstetrics & Gynecology|May 20, 2022
Verification of HPV16 as a good prognostic factor for cervical adeno-adenosquamous carcinoma via an international collaborative studyWei-Chun Chen, Hextan Ys Ngan, Lan-Yan Yang, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
BMC Sports Science, Medicine & Rehabilitation|April 30, 2025
Physical fitness predicts post-esophagectomy complications after chemoradiotherapy: a pilot studyChien-Hung Chiu, Wei-Yang Chang, Lan-Yan Yang, et al.
Current Oncology (Toronto, Ont.)|October 27, 2022
Management and Prognosis of Patients with Recurrent or Persistent/Progressive Uterine CarcinosarcomaHsiu-Jung Tung, Chi-Yuan Chiang, Wei-Yang Chang, et al.
Journal of the Chinese Medical Association : JCMA|November 8, 2021
Serum levels of alpha1-antitrypsin isoforms in patients with ovarian clear cell carcinoma: An exploratory studySung-Yao Chen, Ting-Chang Chang, Chiao-Yun Lin, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|April 9, 2017
Clear cell carcinomas of the ovary have poorer outcomes compared with serous carcinomas: Results from a single-center Taiwanese studyFei-Chun Ku, Ren-Chin Wu, Lan-Yan Yang, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|May 13, 2021
Postoperative adjuvant dose-dense chemotherapy with bevacizumab and maintenance bevacizumab after neoadjuvant chemotherapy for advanced ovarian cancer: A phase II AGOG/TGOG trialHung-Hsueh Chou, Wei-Chun Chen, Lan-Yan Yang, et al.
Journal of Molecular Medicine (Berlin, Germany)|May 5, 2018
Genomic scar signatures associated with homologous recombination deficiency predict adverse clinical outcomes in patients with ovarian clear cell carcinomaAngel Chao, Chyong-Huey Lai, Tzu-Hao Wang, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 11, 2016
Utility of (18)F-FDG PET/CT in patients with advanced squamous cell carcinoma of the uterine cervix receiving concurrent chemoradiotherapy: a parallel study of a prospective randomized trialFeng-Yuan Liu, Chyong-Huey Lai, Lan-Yan Yang, et al.
Journal of Gynecologic Oncology|January 9, 2020
<i>BRCA1/2</i> mutation status in patients with metachronous breast and ovarian malignancies: clues towards the implementation of genetic counselingAngel Chao, Yi Hao Lin, Lan Yan Yang, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|December 11, 2019
Management and clinical outcomes of patients with recurrent/progressive ovarian clear cell carcinomaHuei-Jean Huang, Lan-Yan Yang, Hsiu-Jung Tung, et al.
Taiwanese Journal of Obstetrics & Gynecology|May 20, 2022
Verification of HPV16 as a good prognostic factor for cervical adeno-adenosquamous carcinoma via an international collaborative studyWei-Chun Chen, Hextan Ys Ngan, Lan-Yan Yang, et al.
Pageof 3